SCHEMBL6556758

SCHEMBL6556758

CC(C(=O)Cl)c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.46
ADRA1D P25100 1/20 0.44
HPGD P15428 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.43
ALOX15 P16050 1/20 0.42
PTGS1 P23219 3/20 0.42
MAPT P10636 2/20 0.42
CXCR1 P25024 2/20 0.42
CXCR2 P25025 2/20 0.42
PTGS2 P35354 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
RECQL P46063 1/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPK1 P28482 1/20 0.42
PMP22 Q01453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10980506 0.88 PTGS1 (0.47) HPGDALDH1A1MEN1KMT2AALOX15
SCHEMBL27613551 0.86 TRPM8 (0.48) ACP3ADRA1DHPGDALDH1A1MEN1
SCHEMBL29538369 0.85 PTGS1 (0.59) ACP3HPGDALDH1A1MEN1KMT2A
SCHEMBL1917129 0.85 PTGS1 (0.59) ACP3HPGDALDH1A1MEN1KMT2A
SCHEMBL15641429 0.85 PTGS1 (0.59) ACP3HPGDALDH1A1MEN1KMT2A
SCHEMBL15695557 0.85 PTGS1 (0.46) ACP3ADRA1DHPGDALDH1A1MEN1
SCHEMBL2055566 0.83 TRPM8 (0.52) ACP3ADRA1DTRPM8OGG1PARP1
SCHEMBL10922688 0.83 ACP3 (0.45) ACP3ADRA1DHPGDALDH1A1MEN1
SCHEMBL27705790 0.83 ACP3 (0.49) ACP3ADRA1DHPGDALDH1A1MEN1
SCHEMBL27586341 0.82 MAPT (0.48) HPGDALDH1A1MEN1KMT2AALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704117-B1 AZABICYCLO DERIVATIVES FOR TREATING OCULAR DISORDERS ALCON INC (CH) 2026-01-28 EP disclosed
US-12247028-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2025-03-11 US disclosed
US-20240132497-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2024-04-25 US disclosed
US-11884666-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2024-01-30 US disclosed
US-20220267328-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2022-08-25 US disclosed
US-11306090-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2022-04-19 US disclosed
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2021-06-17 US disclosed
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2021-06-17 US disclosed
EP-3704117-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES FOR TREATING OCULAR DISORDERS ALCON INC. (CH) 2020-09-09 EP disclosed
CN-111247147-A Azabicyclo and diazepatriene derivatives useful for treating ocular disorders 爱尔康公司 2020-06-05 CN disclosed
EP-1423691-A1 FLUORESCENCE BASED OXYGEN SENSOR SYSTEMS 3M Innovative Properties Company (US) 2004-06-02 EP disclosed
US-6664111-B2 The detector is a solid polymeric matrix, e.g., siloxane, modified by a luminescent platinum group metal phenanthroline chelate complex which is quenchable by oxygen; blood and tissue samples; medical diagnosis; compact; lightweight 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
US-20030099574-A1 Fluorescence based oxygen sensor systems 3M INNOVATIVE PROPERTIES COMPANY 2003-05-29 US disclosed
WO-2003019179-A1 FLUORESCENCE BASED OXYGEN SENSOR SYSTEMS 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884666-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 ACP3 3863/4885ADRA1D 103/4885HPGD 1520/4885
US-20240132497-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 ACP3 3863/4885ADRA1D 103/4885HPGD 1520/4885
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 ACP3 3863/4885ADRA1D 103/4885HPGD 1520/4885
US-20220267328-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 ACP3 3863/4885ADRA1D 103/4885HPGD 1520/4885
US-12247028-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 ACP3 3863/4885ADRA1D 103/4885HPGD 1520/4885
US-11306090-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 ACP3 3863/4885ADRA1D 103/4885HPGD 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.